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Variation in HIV prevalence and 
the population-level effects of 
antiretroviral therapy in reducing 
tuberculosis incidence in South Africa
To the Editor: The current year (2018) marks the 10th year after the 
tuberculosis (TB) epidemic in South Africa (SA) reached a historic 
peak of 848 incident TB cases per 100 000 population in 2008.[1,2] TB 
incidence has since decreased at an average of 2.0% annually to 781 per 
100 000 in 2016.[1,2] The decline observed in the past decade has mainly 
been attributed to the expansion of HIV testing and antiretroviral 
therapy (ART).[1,2] Despite these and other public health efforts, TB 
remains a leading cause of death in SA,[1] and at the current rate of 
decline, SA will not reach the 2035 targets of the End TB Strategy.[3]
National-level observational and mathematical modelling studies 
suggest that further scale-up of ART could yield substantial reductions 
in TB incidence and mortality over the next two decades.[4,5] The 
effect of ART on halting and reversing local TB incidence depends 
on the extent to which TB (and transmission) in the population is 
attributable to HIV infection. To date, there is limited information 
about trends in HIV prevalence, ART coverage and TB at subnational 
level in SA. We reviewed data from the National Antenatal Sentinel 
HIV Prevalence Survey[6] and the District Health Barometer[7] to 
compare rates of TB and HIV in the 52 SA health districts. HIV 
prevalence estimates ranged from 2.3% to 46.9% in 2013 and were 
poorly associated with rates of reported TB in the districts (Fig. 1). 
Several districts reported high TB rates (exceeding 700 per 100 000) 
despite relatively low estimates of HIV prevalence. We note that the 
observed variation in HIV and TB rates at subnational level has 
important implications for TB control in SA and therefore deserves 
further investigation. It is currently not known whether varying levels 
of ART coverage in the SA population explain the poor association 
between local TB and HIV rates, or to what extent other factors, such 
as poor TB case detection, initial loss to follow-up, failing delivery of 
integrated HIV-TB services and poor treatment outcomes, contribute 
to ongoing transmission and high TB rates.
We conclude that efforts are needed to better understand 
the determinants of local variation in TB and HIV rates in SA. 
Comprehensive data on the uptake and coverage of ART can guide 
ART scale-up in the forthcoming years and will inform projections of 
the effects that ART will have towards reducing TB in different parts 
of the country. An integrated control strategy that further strengthens 
HIV prevention and treatment but also effectively addresses other 
important barriers to TB control will help the country to make 
significant progress in the forthcoming years.[8]
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Fig. 1. Antenatal HIV prevalence[6] and rates of diagnosed TB cases (all 
forms) per 100 000 population[7] in the 52 SA health districts in 2013 
(Pearson correlation coefficient r=0.21; test for correlation p=0.15). (TB = 
tuberculosis; SA = South Africa/n.)
